BRCA1 and osteosarcoma: Most pertinent to the work reported here is the planned assessment of PARPi within the paediatric MATCH study (NCT03233204), a large-scale precision medicine trial in children, adolescents, and young adults with advanced cancers including osteosarcoma, with use of BRCA1,2 mutation or HRd for patient selection.